Using a special probe for PET imaging of solid tumors
CLDN18.2 Targeting Nanobody Probe for PET Imaging in Solid Tumors
NA · Peking University Cancer Hospital & Institute · NCT05436093
This study is testing a new imaging method to see if a special probe can help find certain solid tumors in patients so they can get better-targeted treatments.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 15 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | Peking University Cancer Hospital & Institute (other) |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05436093 on ClinicalTrials.gov |
What this trial studies
This study aims to develop a noninvasive PET/CT imaging technique using a 68Ga-ACN376 probe to detect the expression of CLDN18.2 in solid tumors. By identifying patients with measurable tumor lesions, the study seeks to determine who may benefit from targeted treatments against CLDN18.2. The approach focuses on enhancing the accuracy of tumor characterization and treatment planning for affected individuals.
Who should consider this trial
Good fit: Ideal candidates include adults over 18 years old with solid tumors and at least one measurable target lesion.
Not a fit: Patients with significant hepatic or renal dysfunction, or those who are pregnant, may not benefit from this study.
Why it matters
Potential benefit: If successful, this could lead to improved detection and treatment options for patients with solid tumors expressing CLDN18.2.
How similar studies have performed: While this approach is innovative, similar studies using targeted imaging for tumor characterization have shown promise in the past.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 1\. Aged \>18 years old; ECOG 0 or 1; * 2\. Patients with solid tumors; * 3\. Has at least one measurable target lesion according to Response Evaluation Criteria in Solid Tumors (RECIST V1.1); * 4\. life expectancy \>=12 weeks. Exclusion Criteria: * 1\. Significant hepatic or renal dysfunction; * 2\. Is pregnant or ready to pregnant; * 3\. Cannot keep their states for half an hour; * 4\. Refusal to join the clinical study; * 5\. Suffering from claustrophobia or other mental diseases; * 6\. Any other situation that researchers think it is not suitable to participate in the experiment.
Where this trial is running
Beijing, Beijing Municipality
- Beijing cancer hospital — Beijing, Beijing Municipality, China (RECRUITING)
Study contacts
- Principal investigator: Hua Zhu — Peking University Cancer Hospital & Institute
- Study coordinator: Hua Zhu
- Email: zhuhuabch@pku.edu.cn
- Phone: 010-88196495
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Solid Tumor